A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example

The oral bioavailability and blood-brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut microbiota and liver can metabolize herbal ingredients to more absorbable forms. The current study aims to evaluate the ability of a novel biotransformatio...

Full description

Saved in:
Bibliographic Details
Published inChinese medicine Vol. 18; no. 1; pp. 40 - 18
Main Authors Hu, En, Li, Zhilin, Li, Teng, Yang, Xueping, Ding, Ruoqi, Jiang, Haoying, Su, Hong, Cheng, Menghan, Yu, Zhe, Li, Haigang, Tang, Tao, Wang, Yang
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 17.04.2023
BioMed Central
BMC
Subjects
Animal experimentation
Animal research
Astragaloside IV
Bioavailability
Biotransformation
Blood-brain barrier
Cdc42 protein
FDA approval
Genes
Gut microbiota
Health aspects
Hemorrhage
Herbal products
Intestinal microflora
Intracerebral hemorrhage
Leukocyte migration
Ligands
Liver
Macrophages
Mathematical models
Medicine, Botanic
Medicine, Herbal
Membrane permeability
Metabolism
Metabolites
Microbiota
Microbiota (Symbiotic organisms)
Microglia
Molecular dynamics
Nervous system diseases
Network pharmacology
Neurological diseases
Permeability
Pharmacology
Proteins
Simulation
Stroke
Traditional Chinese medicine
Tumor necrosis factor-α
China
Beijing China
United States > US
Gut microbiota
Herbal products
Cycloastragenol
Biotransformation
Liver
Network pharmacology
Astragaloside IV
3-epi-cycloastragenol
Intracerebral hemorrhage
Microglia
Online AccessGet full text

Cover

Abstract The oral bioavailability and blood-brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut microbiota and liver can metabolize herbal ingredients to more absorbable forms. The current study aims to evaluate the ability of a novel biotransformation-integrated network pharmacology strategy to discover the therapeutic mechanisms of low-bioavailability herbal products in neurological diseases. A study on the mechanisms of Astragaloside IV (ASIV) in treating intracerebral hemorrhage (ICH) was selected as an example. Firstly, the absorbed ASIV metabolites were collected by a literature search. Next, the ADMET properties and the ICH-associated targets of ASIV and its metabolites were compared. Finally, the biotransformation-increased targets and biological processes were screened out and verified by molecular docking, molecular dynamics simulation, and cell and animal experiments. The metabolites (3-epi-cycloastragenol and cycloastragenol) showed higher bioavailability and blood-brain barrier permeability than ASIV. Biotransformation added the targets ASIV in ICH, including PTK2, CDC42, CSF1R, and TNF. The increased targets were primarily enriched in microglia and involved in cell migration, proliferation, and inflammation. The computer simulations revealed that 3-epi-cycloastragenol bound CSF1R and cycloastragenol bound PTK2 and CDC42 stably. The In vivo and in vitro studies confirmed that the ASIV-derived metabolites suppressed CDC42 and CSF1R expression and inhibited microglia migration, proliferation, and TNF-α secretion. ASIV inhibits post-ICH microglia/macrophage proliferation and migration, probably through its transformed products to bind CDC42, PTK2, and CSF1R. The integrated strategy can be used to discover novel mechanisms of herbal products or traditional Chinses medicine in treating diseases.
AbstractList Abstract Background The oral bioavailability and blood–brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut microbiota and liver can metabolize herbal ingredients to more absorbable forms. The current study aims to evaluate the ability of a novel biotransformation-integrated network pharmacology strategy to discover the therapeutic mechanisms of low-bioavailability herbal products in neurological diseases. Methods A study on the mechanisms of Astragaloside IV (ASIV) in treating intracerebral hemorrhage (ICH) was selected as an example. Firstly, the absorbed ASIV metabolites were collected by a literature search. Next, the ADMET properties and the ICH-associated targets of ASIV and its metabolites were compared. Finally, the biotransformation-increased targets and biological processes were screened out and verified by molecular docking, molecular dynamics simulation, and cell and animal experiments. Results The metabolites (3-epi-cycloastragenol and cycloastragenol) showed higher bioavailability and blood–brain barrier permeability than ASIV. Biotransformation added the targets ASIV in ICH, including PTK2, CDC42, CSF1R, and TNF. The increased targets were primarily enriched in microglia and involved in cell migration, proliferation, and inflammation. The computer simulations revealed that 3-epi-cycloastragenol bound CSF1R and cycloastragenol bound PTK2 and CDC42 stably. The In vivo and in vitro studies confirmed that the ASIV-derived metabolites suppressed CDC42 and CSF1R expression and inhibited microglia migration, proliferation, and TNF-α secretion. Conclusion ASIV inhibits post-ICH microglia/macrophage proliferation and migration, probably through its transformed products to bind CDC42, PTK2, and CSF1R. The integrated strategy can be used to discover novel mechanisms of herbal products or traditional Chinses medicine in treating diseases. Graphical Abstract
The oral bioavailability and blood-brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut microbiota and liver can metabolize herbal ingredients to more absorbable forms. The current study aims to evaluate the ability of a novel biotransformation-integrated network pharmacology strategy to discover the therapeutic mechanisms of low-bioavailability herbal products in neurological diseases. A study on the mechanisms of Astragaloside IV (ASIV) in treating intracerebral hemorrhage (ICH) was selected as an example. Firstly, the absorbed ASIV metabolites were collected by a literature search. Next, the ADMET properties and the ICH-associated targets of ASIV and its metabolites were compared. Finally, the biotransformation-increased targets and biological processes were screened out and verified by molecular docking, molecular dynamics simulation, and cell and animal experiments. The metabolites (3-epi-cycloastragenol and cycloastragenol) showed higher bioavailability and blood-brain barrier permeability than ASIV. Biotransformation added the targets ASIV in ICH, including PTK2, CDC42, CSF1R, and TNF. The increased targets were primarily enriched in microglia and involved in cell migration, proliferation, and inflammation. The computer simulations revealed that 3-epi-cycloastragenol bound CSF1R and cycloastragenol bound PTK2 and CDC42 stably. The In vivo and in vitro studies confirmed that the ASIV-derived metabolites suppressed CDC42 and CSF1R expression and inhibited microglia migration, proliferation, and TNF-[alpha] secretion. ASIV inhibits post-ICH microglia/macrophage proliferation and migration, probably through its transformed products to bind CDC42, PTK2, and CSF1R. The integrated strategy can be used to discover novel mechanisms of herbal products or traditional Chinses medicine in treating diseases.
Background The oral bioavailability and blood-brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut microbiota and liver can metabolize herbal ingredients to more absorbable forms. The current study aims to evaluate the ability of a novel biotransformation-integrated network pharmacology strategy to discover the therapeutic mechanisms of low-bioavailability herbal products in neurological diseases. Methods A study on the mechanisms of Astragaloside IV (ASIV) in treating intracerebral hemorrhage (ICH) was selected as an example. Firstly, the absorbed ASIV metabolites were collected by a literature search. Next, the ADMET properties and the ICH-associated targets of ASIV and its metabolites were compared. Finally, the biotransformation-increased targets and biological processes were screened out and verified by molecular docking, molecular dynamics simulation, and cell and animal experiments. Results The metabolites (3-epi-cycloastragenol and cycloastragenol) showed higher bioavailability and blood-brain barrier permeability than ASIV. Biotransformation added the targets ASIV in ICH, including PTK2, CDC42, CSF1R, and TNF. The increased targets were primarily enriched in microglia and involved in cell migration, proliferation, and inflammation. The computer simulations revealed that 3-epi-cycloastragenol bound CSF1R and cycloastragenol bound PTK2 and CDC42 stably. The In vivo and in vitro studies confirmed that the ASIV-derived metabolites suppressed CDC42 and CSF1R expression and inhibited microglia migration, proliferation, and TNF-[alpha] secretion. Conclusion ASIV inhibits post-ICH microglia/macrophage proliferation and migration, probably through its transformed products to bind CDC42, PTK2, and CSF1R. The integrated strategy can be used to discover novel mechanisms of herbal products or traditional Chinses medicine in treating diseases. Graphical Keywords: Herbal products, Gut microbiota, Biotransformation, Liver, Network pharmacology, Astragaloside IV, Intracerebral hemorrhage, Cycloastragenol, 3-epi-cycloastragenol, Microglia
The oral bioavailability and blood-brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut microbiota and liver can metabolize herbal ingredients to more absorbable forms. The current study aims to evaluate the ability of a novel biotransformation-integrated network pharmacology strategy to discover the therapeutic mechanisms of low-bioavailability herbal products in neurological diseases.BACKGROUNDThe oral bioavailability and blood-brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut microbiota and liver can metabolize herbal ingredients to more absorbable forms. The current study aims to evaluate the ability of a novel biotransformation-integrated network pharmacology strategy to discover the therapeutic mechanisms of low-bioavailability herbal products in neurological diseases.A study on the mechanisms of Astragaloside IV (ASIV) in treating intracerebral hemorrhage (ICH) was selected as an example. Firstly, the absorbed ASIV metabolites were collected by a literature search. Next, the ADMET properties and the ICH-associated targets of ASIV and its metabolites were compared. Finally, the biotransformation-increased targets and biological processes were screened out and verified by molecular docking, molecular dynamics simulation, and cell and animal experiments.METHODSA study on the mechanisms of Astragaloside IV (ASIV) in treating intracerebral hemorrhage (ICH) was selected as an example. Firstly, the absorbed ASIV metabolites were collected by a literature search. Next, the ADMET properties and the ICH-associated targets of ASIV and its metabolites were compared. Finally, the biotransformation-increased targets and biological processes were screened out and verified by molecular docking, molecular dynamics simulation, and cell and animal experiments.The metabolites (3-epi-cycloastragenol and cycloastragenol) showed higher bioavailability and blood-brain barrier permeability than ASIV. Biotransformation added the targets ASIV in ICH, including PTK2, CDC42, CSF1R, and TNF. The increased targets were primarily enriched in microglia and involved in cell migration, proliferation, and inflammation. The computer simulations revealed that 3-epi-cycloastragenol bound CSF1R and cycloastragenol bound PTK2 and CDC42 stably. The In vivo and in vitro studies confirmed that the ASIV-derived metabolites suppressed CDC42 and CSF1R expression and inhibited microglia migration, proliferation, and TNF-α secretion.RESULTSThe metabolites (3-epi-cycloastragenol and cycloastragenol) showed higher bioavailability and blood-brain barrier permeability than ASIV. Biotransformation added the targets ASIV in ICH, including PTK2, CDC42, CSF1R, and TNF. The increased targets were primarily enriched in microglia and involved in cell migration, proliferation, and inflammation. The computer simulations revealed that 3-epi-cycloastragenol bound CSF1R and cycloastragenol bound PTK2 and CDC42 stably. The In vivo and in vitro studies confirmed that the ASIV-derived metabolites suppressed CDC42 and CSF1R expression and inhibited microglia migration, proliferation, and TNF-α secretion.ASIV inhibits post-ICH microglia/macrophage proliferation and migration, probably through its transformed products to bind CDC42, PTK2, and CSF1R. The integrated strategy can be used to discover novel mechanisms of herbal products or traditional Chinses medicine in treating diseases.CONCLUSIONASIV inhibits post-ICH microglia/macrophage proliferation and migration, probably through its transformed products to bind CDC42, PTK2, and CSF1R. The integrated strategy can be used to discover novel mechanisms of herbal products or traditional Chinses medicine in treating diseases.
BackgroundThe oral bioavailability and blood–brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut microbiota and liver can metabolize herbal ingredients to more absorbable forms. The current study aims to evaluate the ability of a novel biotransformation-integrated network pharmacology strategy to discover the therapeutic mechanisms of low-bioavailability herbal products in neurological diseases.MethodsA study on the mechanisms of Astragaloside IV (ASIV) in treating intracerebral hemorrhage (ICH) was selected as an example. Firstly, the absorbed ASIV metabolites were collected by a literature search. Next, the ADMET properties and the ICH-associated targets of ASIV and its metabolites were compared. Finally, the biotransformation-increased targets and biological processes were screened out and verified by molecular docking, molecular dynamics simulation, and cell and animal experiments.ResultsThe metabolites (3-epi-cycloastragenol and cycloastragenol) showed higher bioavailability and blood–brain barrier permeability than ASIV. Biotransformation added the targets ASIV in ICH, including PTK2, CDC42, CSF1R, and TNF. The increased targets were primarily enriched in microglia and involved in cell migration, proliferation, and inflammation. The computer simulations revealed that 3-epi-cycloastragenol bound CSF1R and cycloastragenol bound PTK2 and CDC42 stably. The In vivo and in vitro studies confirmed that the ASIV-derived metabolites suppressed CDC42 and CSF1R expression and inhibited microglia migration, proliferation, and TNF-α secretion.ConclusionASIV inhibits post-ICH microglia/macrophage proliferation and migration, probably through its transformed products to bind CDC42, PTK2, and CSF1R. The integrated strategy can be used to discover novel mechanisms of herbal products or traditional Chinses medicine in treating diseases.
The oral bioavailability and blood-brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut microbiota and liver can metabolize herbal ingredients to more absorbable forms. The current study aims to evaluate the ability of a novel biotransformation-integrated network pharmacology strategy to discover the therapeutic mechanisms of low-bioavailability herbal products in neurological diseases. A study on the mechanisms of Astragaloside IV (ASIV) in treating intracerebral hemorrhage (ICH) was selected as an example. Firstly, the absorbed ASIV metabolites were collected by a literature search. Next, the ADMET properties and the ICH-associated targets of ASIV and its metabolites were compared. Finally, the biotransformation-increased targets and biological processes were screened out and verified by molecular docking, molecular dynamics simulation, and cell and animal experiments. The metabolites (3-epi-cycloastragenol and cycloastragenol) showed higher bioavailability and blood-brain barrier permeability than ASIV. Biotransformation added the targets ASIV in ICH, including PTK2, CDC42, CSF1R, and TNF. The increased targets were primarily enriched in microglia and involved in cell migration, proliferation, and inflammation. The computer simulations revealed that 3-epi-cycloastragenol bound CSF1R and cycloastragenol bound PTK2 and CDC42 stably. The In vivo and in vitro studies confirmed that the ASIV-derived metabolites suppressed CDC42 and CSF1R expression and inhibited microglia migration, proliferation, and TNF-α secretion. ASIV inhibits post-ICH microglia/macrophage proliferation and migration, probably through its transformed products to bind CDC42, PTK2, and CSF1R. The integrated strategy can be used to discover novel mechanisms of herbal products or traditional Chinses medicine in treating diseases.
ArticleNumber 40
Audience Academic
Author Wang, Yang
Yang, Xueping
Su, Hong
Ding, Ruoqi
Hu, En
Cheng, Menghan
Li, Haigang
Yu, Zhe
Tang, Tao
Li, Teng
Li, Zhilin
Jiang, Haoying
Author_xml – sequence: 1
  givenname: En
  surname: Hu
  fullname: Hu, En
– sequence: 2
  givenname: Zhilin
  surname: Li
  fullname: Li, Zhilin
– sequence: 3
  givenname: Teng
  surname: Li
  fullname: Li, Teng
– sequence: 4
  givenname: Xueping
  surname: Yang
  fullname: Yang, Xueping
– sequence: 5
  givenname: Ruoqi
  surname: Ding
  fullname: Ding, Ruoqi
– sequence: 6
  givenname: Haoying
  surname: Jiang
  fullname: Jiang, Haoying
– sequence: 7
  givenname: Hong
  surname: Su
  fullname: Su, Hong
– sequence: 8
  givenname: Menghan
  surname: Cheng
  fullname: Cheng, Menghan
– sequence: 9
  givenname: Zhe
  surname: Yu
  fullname: Yu, Zhe
– sequence: 10
  givenname: Haigang
  surname: Li
  fullname: Li, Haigang
– sequence: 11
  givenname: Tao
  surname: Tang
  fullname: Tang, Tao
– sequence: 12
  givenname: Yang
  orcidid: 0000-0003-0447-3107
  surname: Wang
  fullname: Wang, Yang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37069580$$D View this record in MEDLINE/PubMed
BookMark eNp9U12L1TAQLbLifugf8EECgvjSNb1t2tQXuSx-LCz4or6GNJ3cZk2TmrRX98cLTu7dlb2LSCkNM-ecmUzPnGZHzjvIsucFPS8KXr-JRUlXNKerMqe0qVjOHmUnRVO1OWdVfXTvfJydxnhNKStZyZ9kx2VD65ZxepL9XhPnt2DJaFTwnZGWSNeTASY5G0U64-cgXdQ-jBjwLjduhk2QM_TEwfzTh-9kGiRmlbd-c0PinJJ4gF-T9QEimQdIb5ATLElzBDVIZ-IYidepglSz2QLWDB2Wn4LvFzVHYhxWWEKSNQoTvYkgI8S3O0XQGhIKJdap5kZaH00P5PIb8Q7JGFMQoAtIHWD0IQxyA0RGvCA2J8fJwtPssZY2wrPb71n29cP7Lxef8qvPHy8v1le5Yi2bc63ajqperkrVFy0vO6BQlaUuSln3Umte1bQsW01LXjTAuW5ZVVCuakZbzjB1ll3udXsvr8UUzCjDjfDSiF3Ah42QAWdjQfQtA9YWLWvruqKc8U5iD6CKVmJRVaDWu73WtHQj9ArSTe2B6GHGmUFs_FYUFHuqmgoVXt8qBP9jgTiL0UQF1koHfolixemKc9Y0NUJfPoBe-yU4nFVCof3Keid4i8KfAMI4nUyjkqhYN2k2vOIcUef_QOHTA5oPra0Nxg8Ir-4RBpB2HqK3S_JhPAS-uD-Sv7O4szkC-B6AHo8xgBbKzDs_YwvG4mhE2iix3yiB1xK7jRIMqasH1Dv1_5D-ANANKDI
CitedBy_id crossref_primary_10_1021_acs_jafc_4c10497
crossref_primary_10_1016_j_ijpharm_2025_125186
crossref_primary_10_1016_j_phymed_2024_156149
crossref_primary_10_3389_fphar_2025_1525914
crossref_primary_10_1002_ddr_70038
crossref_primary_10_1016_j_tifs_2024_104804
crossref_primary_10_3389_fmed_2025_1535682
crossref_primary_10_3390_metabo14120683
crossref_primary_10_1016_j_clinthera_2024_11_012
crossref_primary_10_1002_cbdv_202402018
crossref_primary_10_2147_IDR_S491101
crossref_primary_10_3390_ph17111539
crossref_primary_10_1186_s13018_025_05504_w
crossref_primary_10_3389_fphar_2024_1431240
crossref_primary_10_1038_s41598_024_78664_0
crossref_primary_10_1186_s13020_024_00977_z
crossref_primary_10_1016_j_heliyon_2024_e37020
crossref_primary_10_1016_j_phrs_2025_107590
crossref_primary_10_1016_j_tifs_2025_104944
crossref_primary_10_2147_DDDT_S450895
crossref_primary_10_1016_j_molstruc_2024_141128
crossref_primary_10_1080_02652048_2025_2469259
crossref_primary_10_1002_ajoc_202400549
crossref_primary_10_1016_j_bbr_2025_115521
crossref_primary_10_1016_j_ejmech_2025_117357
crossref_primary_10_3389_fphar_2024_1513694
crossref_primary_10_1016_j_lwt_2025_117491
crossref_primary_10_1007_s11011_025_01558_1
crossref_primary_10_3390_biom15010093
Cites_doi 10.1080/00498254.2016.1204568
10.1016/j.smim.2021.101511
10.1016/j.phrs.2022.106200
10.1016/j.intimp.2022.109290
10.1038/nbt1284
10.1016/j.bioorg.2022.105975
10.1101/cshperspect.a021857
10.1016/j.jnutbio.2013.05.001
10.1021/acs.jafc.1c06110
10.1016/j.jep.2022.115629
10.1186/s12974-020-01791-8
10.1093/nar/gkx374
10.1016/j.phrs.2019.02.024
10.1016/j.jep.2021.114699
10.1093/nar/gku293
10.3389/fphar.2022.977539
10.1038/ng0504-431
10.1021/acs.jnatprod.9b01285
10.3390/nu14234968
10.1016/j.cld.2016.08.001
10.1002/cmdc.201600182
10.1523/JNEUROSCI.1359-19.2019
10.1093/nar/gkz382
10.2967/jnumed.121.262279
10.3389/fmicb.2022.956378
10.1007/s11910-021-01144-9
10.1038/srep42717
10.1038/ncomms9255
10.1021/acs.jafc.5b00168
10.1038/s41401-020-0386-6
10.3389/fmolb.2021.667067
10.1177/0271678X16666551
10.1074/jbc.M109.036384
10.1093/bioinformatics/bty707
10.1021/ci500467k
10.3390/nu14193980
10.4103/ijp.ijp_374_21
10.1016/j.pneurobio.2019.04.001
10.1038/nrm1549
10.1038/s41419-021-04424-x
10.1001/jamaneurol.2020.4152
10.3390/plants11192617
10.1186/s13020-020-00361-7
10.4014/jmb.1807.07020
10.1016/j.intimp.2020.107335
10.2133/dmpk.DMPK-11-RG-160
10.1038/sj.onc.1203877
10.1096/fj.202000550RR
10.1038/s41598-019-40621-7
10.1039/C5NP00005J
10.1155/2018/8916938
10.3724/SP.J.1009.2013.00110
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
NPM
3V.
7T5
7TM
7X7
7XB
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GHDGH
H94
K9.
M0S
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
RC3
7X8
5PM
DOA
DOI 10.1186/s13020-023-00745-5
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Nucleic Acids Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central (NC Live)
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Central China
ProQuest Central
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Immunology Abstracts
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList



MEDLINE - Academic
Publicly Available Content Database
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1749-8546
EndPage 18
ExternalDocumentID oai_doaj_org_article_d95e5919596640858ba595ec19a0e4c1
PMC10108474
A746038488
37069580
10_1186_s13020_023_00745_5
Genre Journal Article
GeographicLocations China
Beijing China
United States--US
GeographicLocations_xml – name: China
– name: Beijing China
– name: United States--US
GrantInformation_xml – fundername: Fundamental Research Funds for Central Universities of the Central South University
  grantid: 2021zzts0351
– fundername: National Natural Science Foundation of China
  grantid: 82174259
– fundername: Hunan TCM Scientific Research Program
  grantid: 2021032
– fundername: The Leadership Training Project of HNATCM
  grantid: 2022-24
– fundername: Key Research and Development Program of Hunan Province of China
  grantid: 2022SK2015
– fundername: Fundamental Research Funds for Central Universities of the Central South University
  grantid: 2021zzts0341
– fundername: Shennong Young Scholar Foundation of Hunan Province
  grantid: 2022
– fundername: The Excellent Clinical Talent Training Project of SATCM
  grantid: 2022-543313
– fundername: National Natural Science Foundation of China
  grantid: 81874425
– fundername: Fundamental Research Funds for Central Universities of the Central South University
  grantid: 2022ZZTS0878
– fundername: ;
  grantid: 2021032
– fundername: ;
  grantid: 81874425; 82174259
– fundername: ;
  grantid: 2021zzts0351; 2021zzts0341; 2022ZZTS0878
– fundername: ;
  grantid: 2022-24
– fundername: ;
  grantid: 2022-543313
– fundername: ;
  grantid: 2022
– fundername: ;
  grantid: 2022SK2015
GroupedDBID ---
0R~
29B
2WC
53G
5GY
5VS
6J9
6PF
7X7
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GS5
GX1
HMCUK
HYE
IAO
IHR
IHW
ITC
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TUS
UKHRP
UNMZH
WOQ
WOW
~8M
-5E
-5G
-A0
-BR
3V.
ACRMQ
ADINQ
C24
M~E
NPM
PMFND
7T5
7TM
7XB
8FD
8FK
AZQEC
DWQXO
FR3
H94
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c595t-fc9b0cda23cd1983be0e433f13a6daff8460339f03817e88f954108c650985033
IEDL.DBID 7X7
ISSN 1749-8546
IngestDate Wed Aug 27 00:16:35 EDT 2025
Thu Aug 21 18:38:01 EDT 2025
Fri Jul 11 09:14:58 EDT 2025
Mon Jun 30 12:00:08 EDT 2025
Tue Jun 17 21:10:11 EDT 2025
Tue Jun 10 20:45:57 EDT 2025
Thu May 22 21:14:05 EDT 2025
Thu Jan 02 22:51:55 EST 2025
Thu Apr 24 23:11:32 EDT 2025
Tue Jul 01 01:00:04 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Gut microbiota
Herbal products
Cycloastragenol
Biotransformation
Liver
Network pharmacology
Astragaloside IV
3-epi-cycloastragenol
Intracerebral hemorrhage
Microglia
Language English
License 2023. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c595t-fc9b0cda23cd1983be0e433f13a6daff8460339f03817e88f954108c650985033
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-0447-3107
OpenAccessLink https://www.proquest.com/docview/2803023674?pq-origsite=%requestingapplication%
PMID 37069580
PQID 2803023674
PQPubID 54985
PageCount 18
ParticipantIDs doaj_primary_oai_doaj_org_article_d95e5919596640858ba595ec19a0e4c1
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10108474
proquest_miscellaneous_2802885776
proquest_journals_2803023674
gale_infotracmisc_A746038488
gale_infotracacademiconefile_A746038488
gale_healthsolutions_A746038488
pubmed_primary_37069580
crossref_citationtrail_10_1186_s13020_023_00745_5
crossref_primary_10_1186_s13020_023_00745_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-04-17
PublicationDateYYYYMMDD 2023-04-17
PublicationDate_xml – month: 04
  year: 2023
  text: 2023-04-17
  day: 17
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Chinese medicine
PublicationTitleAlternate Chin Med
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References M Shahbaaz (745_CR41) 2019; 9
X Wang (745_CR32) 2017; 45
S Hernandez (745_CR37) 2021; 8
A Daina (745_CR28) 2014; 54
T Duan (745_CR18) 2022; 179
M Kibble (745_CR4) 2015; 32
VL Feigin (745_CR16) 2021; 78
M Li (745_CR48) 2017; 37
SM Smolders (745_CR42) 2019; 178
DJ Newman (745_CR1) 2020; 83
A Daina (745_CR27) 2017; 7
P Ma (745_CR38) 2017; 47
S Li (745_CR3) 2013; 11
A Vidal-Limon (745_CR40) 2022; 70
MJ Keiser (745_CR30) 2007; 25
Y Wan (745_CR13) 2022; 13
C Barca (745_CR45) 2022; 63
L Sun (745_CR8) 2022; 283
SK Mitra (745_CR49) 2005; 6
Y Zhao (745_CR9) 2022; 298
ER Stanley (745_CR44) 2014; 6
D Gfeller (745_CR39) 2014; 42
JT Parsons (745_CR50) 2000; 19
A Daina (745_CR31) 2019; 47
R Sadler (745_CR36) 2020; 40
V Chitu (745_CR43) 2021; 54
A Daina (745_CR29) 2016; 11
Z Rong (745_CR51) 2020; 34
I Choi (745_CR52) 2015; 6
745_CR11
Y Zhong (745_CR10) 2018; 2018
Y Zheng (745_CR17) 2022; 127
X Li (745_CR47) 2022; 13
Y Zhao (745_CR7) 2022; 13
L Tan (745_CR33) 2020; 15
Q Li (745_CR25) 2019; 29
R Zhou (745_CR21) 2012; 27
L Li (745_CR20) 2021; 92
M Li (745_CR24) 2020; 41
H Yang (745_CR26) 2019; 35
W Feng (745_CR6) 2019; 142
HA Alomar (745_CR2) 2022; 11
OA Almazroo (745_CR14) 2017; 21
M Shi (745_CR35) 2022; 54
KG Becker (745_CR34) 2004; 36
F Cardona (745_CR5) 2013; 24
Y Jin (745_CR22) 2015; 63
T Chen (745_CR23) 2022; 113
S Zhang (745_CR12) 2022; 14
ML Xia (745_CR19) 2020; 17
M Cammer (745_CR46) 2009; 284
H Kirshner (745_CR15) 2021; 21
References_xml – volume: 47
  start-page: 526
  year: 2017
  ident: 745_CR38
  publication-title: Xenobiotica
  doi: 10.1080/00498254.2016.1204568
– volume: 54
  year: 2021
  ident: 745_CR43
  publication-title: Semin Immunol
  doi: 10.1016/j.smim.2021.101511
– volume: 179
  year: 2022
  ident: 745_CR18
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2022.106200
– volume: 113
  year: 2022
  ident: 745_CR23
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2022.109290
– volume: 25
  start-page: 197
  year: 2007
  ident: 745_CR30
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt1284
– volume: 127
  year: 2022
  ident: 745_CR17
  publication-title: Bioorg Chem
  doi: 10.1016/j.bioorg.2022.105975
– volume: 6
  year: 2014
  ident: 745_CR44
  publication-title: Cold Spring Harb Perspect Biol
  doi: 10.1101/cshperspect.a021857
– volume: 24
  start-page: 1415
  year: 2013
  ident: 745_CR5
  publication-title: J Nutr Biochem
  doi: 10.1016/j.jnutbio.2013.05.001
– volume: 70
  start-page: 934
  year: 2022
  ident: 745_CR40
  publication-title: J Agric Food Chem
  doi: 10.1021/acs.jafc.1c06110
– volume: 298
  year: 2022
  ident: 745_CR9
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2022.115629
– volume: 17
  start-page: 105
  year: 2020
  ident: 745_CR19
  publication-title: J Neuroinflammation
  doi: 10.1186/s12974-020-01791-8
– volume: 45
  start-page: W356
  year: 2017
  ident: 745_CR32
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkx374
– volume: 142
  start-page: 176
  year: 2019
  ident: 745_CR6
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2019.02.024
– volume: 283
  year: 2022
  ident: 745_CR8
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2021.114699
– volume: 42
  start-page: W32
  year: 2014
  ident: 745_CR39
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gku293
– volume: 13
  year: 2022
  ident: 745_CR13
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2022.977539
– volume: 36
  start-page: 431
  year: 2004
  ident: 745_CR34
  publication-title: Nat Genet
  doi: 10.1038/ng0504-431
– volume: 83
  start-page: 770
  year: 2020
  ident: 745_CR1
  publication-title: J Nat Prod
  doi: 10.1021/acs.jnatprod.9b01285
– ident: 745_CR11
  doi: 10.3390/nu14234968
– volume: 21
  start-page: 1
  year: 2017
  ident: 745_CR14
  publication-title: Clin Liver Dis
  doi: 10.1016/j.cld.2016.08.001
– volume: 11
  start-page: 1117
  year: 2016
  ident: 745_CR29
  publication-title: ChemMedChem
  doi: 10.1002/cmdc.201600182
– volume: 40
  start-page: 1162
  year: 2020
  ident: 745_CR36
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.1359-19.2019
– volume: 47
  start-page: W357
  year: 2019
  ident: 745_CR31
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkz382
– volume: 63
  start-page: 446
  year: 2022
  ident: 745_CR45
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.121.262279
– volume: 13
  year: 2022
  ident: 745_CR7
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2022.956378
– volume: 21
  start-page: 57
  year: 2021
  ident: 745_CR15
  publication-title: Curr Neurol Neurosci Rep
  doi: 10.1007/s11910-021-01144-9
– volume: 7
  start-page: 42717
  year: 2017
  ident: 745_CR27
  publication-title: Sci Rep
  doi: 10.1038/srep42717
– volume: 6
  start-page: 8255
  year: 2015
  ident: 745_CR52
  publication-title: Nat Commun
  doi: 10.1038/ncomms9255
– volume: 63
  start-page: 6084
  year: 2015
  ident: 745_CR22
  publication-title: J Agric Food Chem
  doi: 10.1021/acs.jafc.5b00168
– volume: 41
  start-page: 1025
  year: 2020
  ident: 745_CR24
  publication-title: Acta Pharmacol Sin
  doi: 10.1038/s41401-020-0386-6
– volume: 8
  year: 2021
  ident: 745_CR37
  publication-title: Front Mol Biosci
  doi: 10.3389/fmolb.2021.667067
– volume: 37
  start-page: 2383
  year: 2017
  ident: 745_CR48
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1177/0271678X16666551
– volume: 284
  start-page: 23302
  year: 2009
  ident: 745_CR46
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M109.036384
– volume: 35
  start-page: 1067
  year: 2019
  ident: 745_CR26
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/bty707
– volume: 54
  start-page: 3284
  year: 2014
  ident: 745_CR28
  publication-title: J Chem Inf Model
  doi: 10.1021/ci500467k
– volume: 14
  start-page: 3980
  year: 2022
  ident: 745_CR12
  publication-title: Nutrients
  doi: 10.3390/nu14193980
– volume: 54
  start-page: 110
  year: 2022
  ident: 745_CR35
  publication-title: Indian J Pharmacol
  doi: 10.4103/ijp.ijp_374_21
– volume: 178
  year: 2019
  ident: 745_CR42
  publication-title: Prog Neurobiol
  doi: 10.1016/j.pneurobio.2019.04.001
– volume: 6
  start-page: 56
  year: 2005
  ident: 745_CR49
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm1549
– volume: 13
  start-page: 33
  year: 2022
  ident: 745_CR47
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-021-04424-x
– volume: 78
  start-page: 165
  year: 2021
  ident: 745_CR16
  publication-title: Jama Neurol
  doi: 10.1001/jamaneurol.2020.4152
– volume: 11
  start-page: 2617
  year: 2022
  ident: 745_CR2
  publication-title: Plants
  doi: 10.3390/plants11192617
– volume: 15
  start-page: 79
  year: 2020
  ident: 745_CR33
  publication-title: Chin Med
  doi: 10.1186/s13020-020-00361-7
– volume: 29
  start-page: 1882
  year: 2019
  ident: 745_CR25
  publication-title: J Microbiol Biotechnol
  doi: 10.4014/jmb.1807.07020
– volume: 92
  year: 2021
  ident: 745_CR20
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2020.107335
– volume: 27
  start-page: 586
  year: 2012
  ident: 745_CR21
  publication-title: Drug Metab Pharmacokinet
  doi: 10.2133/dmpk.DMPK-11-RG-160
– volume: 19
  start-page: 5606
  year: 2000
  ident: 745_CR50
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1203877
– volume: 34
  start-page: 10984
  year: 2020
  ident: 745_CR51
  publication-title: FASEB J
  doi: 10.1096/fj.202000550RR
– volume: 9
  start-page: 4405
  year: 2019
  ident: 745_CR41
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-40621-7
– volume: 32
  start-page: 1249
  year: 2015
  ident: 745_CR4
  publication-title: Nat Prod Rep
  doi: 10.1039/C5NP00005J
– volume: 2018
  start-page: 1
  year: 2018
  ident: 745_CR10
  publication-title: Evid Based Complement Alternat Med
  doi: 10.1155/2018/8916938
– volume: 11
  start-page: 110
  year: 2013
  ident: 745_CR3
  publication-title: Chin J Nat Med
  doi: 10.3724/SP.J.1009.2013.00110
SSID ssj0053538
Score 2.508091
Snippet The oral bioavailability and blood-brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut microbiota and...
Background The oral bioavailability and blood-brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut...
BackgroundThe oral bioavailability and blood–brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut...
Abstract Background The oral bioavailability and blood–brain barrier permeability of many herbal products are too low to explain the significant efficacy...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 40
SubjectTerms Animal experimentation
Animal research
Astragaloside IV
Bioavailability
Biotransformation
Blood-brain barrier
Cdc42 protein
FDA approval
Genes
Gut microbiota
Health aspects
Hemorrhage
Herbal products
Intestinal microflora
Intracerebral hemorrhage
Leukocyte migration
Ligands
Liver
Macrophages
Mathematical models
Medicine, Botanic
Medicine, Herbal
Membrane permeability
Metabolism
Metabolites
Microbiota
Microbiota (Symbiotic organisms)
Microglia
Molecular dynamics
Nervous system diseases
Network pharmacology
Neurological diseases
Permeability
Pharmacology
Proteins
Simulation
Stroke
Traditional Chinese medicine
Tumor necrosis factor-α
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yD-KL-G311AiCDxKubZI29W0Vj1M4nzy5t5AmKbtwmy7bPeH-eMGZpFu3CPriazJJ2slkZsJMfkPIm0Jam_PSMNNJw0RX1qwRnWOV43ULG176CJl__rU6uxBfLuXlQakvzAlL8MCJcSeukV42CIFSVYjGpVojockWjcm9sPHiAzZvf5lKOlhyOMf7JzKqOhkwPJczsE8MbaZkcmaGIlr_nzr5wCjNEyYPLNDpPXJ3dB3pIn3yfXLLhwfk9vkYHH9Ifi5o6H_4K7peRXQloDXB0aXHpGlL21W_O_BS-8AmqAhHQ8oGp5vfSNY3dEjItTfUx0Q9P1DwFunBiy269vhweDWsB9p3uIKJ6hPW3Law_CbByQ50FWgEzhwVLR3DQsP7OOOYU4JTLHBNYFCPVUTp5--0DzAY2qzfYoj7CqZe99vtEtQgNQP8IHycQYTjR-Ti9NO3j2dsrO7ALGzgjnW2aXPrTMmtKxrFWw_7yXlXcFM503XgGOWcN13EEPRKdY0URa4sQv4pDL4-JkehD_4poUK6QpimrGpw77xpG-5yI8AzldI7x31Giv1maztCn2MFjisdr0Cq0klANAiIjgKiZUbeTWM2Cfjjr9QfUIYmSgTtjg0gynoUZf0vUc7IK5RAnV7ATqpHL2pkhQJVm5G3kQKVD7LejG8ogA0I4zWjPJ5RgtKw8-69lOtRaQ0aC5VhQYFaZOT11I0jMREv-P460pRKybquMvIkHYrpp3mdV41UeUbU7LjMuDLvCatlhDQHw5CDnySe_Q8-Pid3ynjUBSvqY3K02177F-A67tqXUUv8As1nb6w
  priority: 102
  providerName: Directory of Open Access Journals
Title A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example
URI https://www.ncbi.nlm.nih.gov/pubmed/37069580
https://www.proquest.com/docview/2803023674
https://www.proquest.com/docview/2802885776
https://pubmed.ncbi.nlm.nih.gov/PMC10108474
https://doaj.org/article/d95e5919596640858ba595ec19a0e4c1
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3_a9QwFA-6gfiL-N3qPCMI_iBhbdO0ib_ITTbmwYaok_1W0iR1B7v2vN6E_fGC76W57oqwnwrNS9IkL5-8Ji-fR8i7RBgT81QzXQvNsjotmMpqy3LLiwoGPHWeMv_kND8-y2bn4jxsuHXBrXKDiR6obWtwj3wfoygh23mRfVr-Zhg1Ck9XQwiNu2QXqctQq4vz4YdLcOEjWYPRrZgUWb65NCPz_Q4P7GIGJTJcRQUTo4XJ8_f_j9Jby9TYhXJrTTp6SB4EY5JO-9F_RO645jG5dxKOy5-Qv1PatH_cJV3MPd8SyOrG0guHbtSGVvN2vWW3tg0byCMsbXr_cLq84ba-pl3PZXtNnXfdcx0F-5Fu3eGiC4dXiefdoqNtjTVoD6hQ56qC6pc9wWxH5w31VJoBemk4KOo--hKDlwkWMcU6oYNajCtKv_ykbQOZ4Z1xKzz0voSiF-1qdQHASHUHDYSP08h5_JScHR3--HzMQrwHZoQSa1YbVcXG6pQbmyjJKxe7jPM64Tq3uq7BVIo5V7VnFXRS1kpkSSwNkgBKPI59RnaatnEvCM2ETTKt0rwAg8_pSnEb6wxsVSGctdxFJNkMdmkCGTrG5Lgs_U-RzMteQUpQkNIrSCki8mHIs-ypQG6VPkAdGiSRxtu_aFe_yoAKpVXCCYWam-dINScrDT3hTKI0NN0kEXmDGlj2d2IHMCqnBXaFBPCNyHsvgXCEXa_DrQroBiT2GknujSQBRsw4eaPlZYCxrryZdBF5OyRjTnTNa1x75WVSKUVR5BF53k-KodG8iHMlZBwROZouo14ZpzTzC09yDktFDJZT9vL273pF7qd-EmcsKfbIznp15V6DmbiuJh4LJmR3Op19n8Hz4PD067eJ33T5ByumbgE
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4k2gUCOBOCCrSRwnDhJCy6Nq6ePUot5cx3bYlbrJstmC-qf4h0jMONl0I6Teeo3HduyMvxnH428IeR0JY0Iea6ZLoVlSxhnLk9Ky1PKsgA8eO0-Zf3CY7hwn307EyRr5s7wLg2GVS0z0QG1rg__ItzCLErKdZ8nH2U-GWaPwdHWZQqNViz138Ru2bM2H3S_wfd_E8fbXo887rMsqwIzIxYKVJi9CY3XMjYUdNy9c6BLOy4jr1OqyBIMccp6XnrvOSVnmIolCaZBqTuKhH7R7g9wEwxviZi876Td4ggufORuc_JxJkaTLSzoy3WrwgDBkMAKGVlswMTCEPl_A_1ZhxSwOQzZXbOD2PXK3c17pqNW2-2TNVQ_IrYPueP4h-TuiVf3LndHpxPM7gayuLB07DNs2tJjUixU_ua5YT1ZhadXGo9PZJZf2BW1a7twL6nyooGso-Kt05c4YnTq8ujxppg2tS-xBewCHPucFdD9rCW0bOqmop-7soJ52B1PNe99iF9WCTYywT5igGvOY0t3vtK6gMjwzbo6H7GfQ9LSez8cAxFQ3MEB4OY0cy4_I8bVowmOyXtWVe0poImyU6DxOM3AwnS5ybkOdgG8shLOWu4BEy4-tTEe-jjlAzpTfhMlUtQqiQEGUVxAlAvKurzNrqUeulP6EOtRLIm24f1DPf6gOhZTNhRM58gmlKVLbyULDTDgT5RqGbqKAbKIGqvYObg9-apThVEgA-4C89RIIfzj1urvFAdOARGIDyY2BJMCWGRYvtVx1sNmoy0UekFd9MdbEUMDK1edeJpZSZFkakCftougHzbMwzYUMAyIHy2UwK8OSajL2pOpgmkLw1JJnV7_XJrm9c3Swr_Z3D_eekzuxX9AJi7INsr6Yn7sX4KIuipceFyg5vW4g-gdz5qWB
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+novel+microbial+and+hepatic+biotransformation-integrated+network+pharmacology+strategy+explores+the+therapeutic+mechanisms+of+bioactive+herbal+products+in+neurological+diseases%3A+the+effects+of+Astragaloside+IV+on+intracerebral+hemorrhage+as+an+example&rft.jtitle=Chinese+medicine&rft.au=Hu%2C+En&rft.au=Li%2C+Zhilin&rft.au=Li%2C+Teng&rft.au=Yang%2C+Xueping&rft.date=2023-04-17&rft.pub=BioMed+Central&rft.eissn=1749-8546&rft.volume=18&rft_id=info:doi/10.1186%2Fs13020-023-00745-5&rft.externalDocID=PMC10108474
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1749-8546&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1749-8546&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1749-8546&client=summon